Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2013.09.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Posaconazole: An Update of Its Clinical Use

Pharmacy
2015English

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine
Medicine
2012English

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology
Hematology
2015English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal
OncologyHematology
2014English

Critical Appraisal of the Role of Ruxolitinib in Myeloproliferative Neoplasm-Associated Myelofibrosis

OncoTargets and Therapy
OncologyPharmacology
2015English

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

BMC Nephrology
Nephrology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy